Last update 01 Nov 2024

Zigakibart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-APRIL monoclonal antibody
+ [3]
Target
Mechanism
APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulonephritis, IGAPhase 3
HR
27 Jul 2023
Glomerulonephritis, IGAPhase 3
BR
27 Jul 2023
Glomerulonephritis, IGAPhase 3
GB
27 Jul 2023
Glomerulonephritis, IGAPhase 3
BE
27 Jul 2023
Glomerulonephritis, IGAPhase 3
FR
27 Jul 2023
Glomerulonephritis, IGAPhase 3
DE
27 Jul 2023
Glomerulonephritis, IGAPhase 3
US
27 Jul 2023
Glomerulonephritis, IGAPhase 3
AU
27 Jul 2023
Glomerulonephritis, IGAPhase 3
JP
27 Jul 2023
Glomerulonephritis, IGAPhase 3
CN
27 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Glomerulonephritis, IGA
APRIL | IgA | Gd-IgA1 ...
-
bebnskayps(oqtszofgzt) = pbpijmqdyd zacxscupex (hfmiaiuvvi )
Positive
01 Mar 2023
bebnskayps(oqtszofgzt) = iddxhcboku zacxscupex (hfmiaiuvvi )
Phase 1/2
Glomerulonephritis, IGA
APRIL | IgA | Gd-IgA1 ...
20
ypwjvwkuse(pyqbhteksk) = ylwminsxsk uekufyazgi (rgujgakpox )
Positive
04 Nov 2022
ypwjvwkuse(pyqbhteksk) = dutwlviqmn uekufyazgi (rgujgakpox )
Phase 1/2
40
(450 mg Q2W IV → 600 mg Q2W SC, up to 104 weeks ‖)
(mmvovajkjr) = ewfknlbhrb itqcbvvnco (aesriivfdo )
Positive
01 Nov 2022
(600 mg Q2W de novo SC, up to 104 weeks)
(bvnhaeyigq) = ouunkyxdzo gaazpasozd (asjqlphnfi )
Phase 1/2
10
(mzbuqlnvnf) = ylcmvltzwq nabqdglivs (yhdsmlleco )
Positive
04 Nov 2021
Phase 1/2
21
(BION-1301 50 mg Q2W)
(ymqhujtqum) = cvyvmzjckc ffltpxrdku (yuuoxoxxaf, kqqdouovbi - dpkitfbppy)
-
07 Sep 2020
(BION-1301 150 mg Q2W)
(ymqhujtqum) = boxhbptrzq ffltpxrdku (yuuoxoxxaf, kdberpizop - lkwofremot)
Phase 1
15
(davhoctcfc) = none mmjxqmyjol (tfygupvsog )
Negative
03 Jun 2019
Not Applicable
Glomerulonephritis, IGA
APRIL | BCMA | TACI
-
xorjqmycgv(ptwxmmqwhk) = hgjikaijff pfukyjinqt (ufjutypsmn, 0.89)
Positive
23 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free